Overview

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.
Phase:
Phase 3
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Eliglustat